Baxter International IncNYSE: BAX
Health Care · Health Care Equipment
$17.35
-1.34%
Vol: 8.4M
Research Digest
Friday, May 1, 2026
Baxter swings to Q1 loss; guidance implies caution despite new product launches
Baxter reported Q1 2026 net sales of $2.70B (+3%) but net loss of $15M vs. $126M profit YoY; adjusted EPS fell 35% to $0.36. Injectables sales down 13% due to manufacturing disruption. New product launches and GPS improvement initiatives ongoing. Full-year guidance: flat to 1% growth, EPS $1.85-$2.05. CFO Joel Grade departing.
Previous Market Intelligence
13 daysApr 30Baxter International beats Q1 revenue but faces analyst caution on structural headwindsMixed▶
Baxter reported Q1 2026 revenue of $2.70B, up 2.9% YoY, with non-GAAP EPS of $0.36, beating estimates by 15.9%. However, stock dropped 5.8% pre-earnings due to revenue concerns. Analysts remain cautious citing dividend cut, quality issues, and flat revenue outlook for next 12 months.
Apr 16Baxter issued FY 2026 guidance on April 9 above consensus; Q1 earnings call April 30Positive▶
Baxter International provided FY 2026 guidance on April 9, 2026 exceeding analyst expectations. Revenue guidance $11.2-11.4B (vs. $11.3B consensus), EPS guidance $1.85-2.05 (vs. $1.93 consensus). Baxter showcased new products at AORN Global Surgical Conference April 11-14: AAT XR spine surgical table (available H2 2026) and Dynamo Series smart stretcher. Institutional investor Greenhaven Associates added 3.6M shares. Evercore maintained Outperform rating but reduced price target from $23 to $22.
Apr 15Baxter International provided FY 2026 guidance and showcased surgical innovations at AORN conference April 11-14; Q1 earnings April 30.Mixed▶
Baxter provided FY 2026 guidance on April 9 forecasting revenue of $11.2-$11.4B and EPS of $1.85-$2.05. The company highlighted recent product launches including the AAT XR spine surgical table at the AORN Global Surgical Conference. BAX anticipates challenges in Q1 before improvements in later quarters. Current stock price is $17.15, with analyst consensus Hold at $22.12 fair value.
Apr 14Baxter International showcases surgical innovations at AORN conference and raises FY 2026 guidance; Q1 earnings call set for April 30.Mixed▶
Baxter International highlighted surgical portfolio additions at AORN conference including the AAT XR spine surgical table (expected H2 2026) and Dynamo Series smart stretcher. Raised FY 2026 revenue guidance to $11.2-$11.4 billion and EPS guidance to $1.85-$2.05. Faced leadership transition with interim CFO appointment.
Apr 13Baxter updates FY 2026 guidance to $1.85-$2.05 EPS with Q1 results conference April 30.Neutral▶
Baxter International issued FY 2026 EPS guidance of $1.85-$2.05 and revenue guidance of $11.2-$11.4 billion. Evercore dropped price target from $23 to $22 with Outperform rating. Consensus analyst rating is Hold with average price target of $19.80. Q1 conference call set for April 30.
Apr 10Baxter International lowered FY 2026 guidance and faces CFO transition; stock at 30-year low.Negative▶
Baxter International provided conservative FY 2026 guidance with EPS of $1.85-$2.05 (below consensus) and revenue of $11.2B-$11.4B. CFO Joel Grade departing with Anita Zielinski as interim CFO. Stock at 30-year low of $16.66 with 49.5% one-year loss. Recent positive: IV Verify Line Labeling System launch. Analysts rate Hold (2 Buy, 9 Hold, 2 Sell) with $19.80 target. Q1 results April 30.
Apr 9Baxter International faces mixed sentiment with weak Q4 results and leadership transitionNegative▶
Baxter reported Q4 2025 adjusted EPS of $0.44, significantly below guidance of $0.52-$0.57 and estimates of $0.54. CFO Joel Grade departed in March 2026 with interim CFO appointed. Company appointed new CFO amid leadership transition. New products like Dynamo Series smart stretcher aimed at growth. Q1 2026 earnings call scheduled April 30. Analysts rate Hold with $22.13 price target.
Apr 8Baxter International reports challenging Q4 with EPS miss; interim CFO appointed amid leadership transitionNegative▶
Baxter International faces headwinds after weak Q4 2025 results with adjusted EPS of $0.44 vs guidance of $0.52-$0.57, disappointing Wall Street. CFO Joel Grade departed and interim CFO appointed. Company introduced Dynamo Series smart stretcher to address hospital challenges. Analysts maintain cautious Hold outlook.
Apr 7No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 6Baxter Q4 2025 disappointing; CFO Joel Grade departed.Negative▶
Baxter reported Q4 2025 adjusted EPS $0.44, below guidance $0.52-$0.57 and consensus $0.54. CFO Joel Grade departed; interim CFO appointed. FY26 EPS guidance $1.85-$2.05. Q4 revenue masked by weak profitability and unfavorable mix.
Apr 3Baxter appoints interim CFO on March 16; product launch of IV Verify on March 31; caution remains on 2026 guidance.Neutral▶
Baxter's CFO Joel Grade stepped down March 16, with Anita Zielinski appointed as interim CFO. Product launch IV Verify announced March 31 to enhance IV labeling accuracy. Management maintains cautious 2026 guidance: flat organic growth, 13-14% operating margin, $1.85-$2.05 EPS.
Apr 2Baxter misses Q4 guidance significantly; CFO Joel Grade departs as company navigates product challenges and legal scrutiny.Negative▶
Baxter reported Q4 adjusted EPS of $0.44, below guidance of $0.52-$0.57 and estimates of $0.54. CFO Joel Grade is departing with Anita Zielinski as interim CFO. Stock down 19.67% in 30 days, down 49.5% over 12 months. Product challenges and Novum LVP legal issues persist despite new product launches.
Apr 1Baxter reports weak Q4 EPS miss ($0.44 vs. $0.54 guidance) and appoints interim CFO.Negative▶
Baxter reported Q4 2025 adjusted EPS of $0.44, missing management guidance of $0.52-$0.57. Revenue reached $2.97B. CFO Joel Grade departed; Anita Zielinski appointed interim CFO. Stock down 35.5% annually.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| BAXBAXTER | $17.35 | -1.34% | +5.6% | 8.7x | 0.62 | $9.1B |
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.